| Insulin (human) recombinant expressed in yeastEndogenous insulin receptor agonist |

Sample solution is provided at 25 µL, 10mM.
Nature.2017 Jan 19;541(7637):417-420.
Nature.2018 Nov;563(7731):407-411.
Nature.2018 Jun 13.
Nature.2018 Jun 27.
Nature.2018 Mar 29;555(7698):673-677.
Nature.2017 Sep 7;549(7670):96-100.
Nature.2016 Apr 21;532(7599):398-401.
Science.2016 Aug 5;353(6299)594-8
Nat Nanotechnol.2017 Dec;12(12):1190-1198.
Nature Biotechnology.2017 Jun;35(6):569-576
Nat Med.2018 Sep 17.
Cell.2018 Dec 21. pii: S0092-8674(18)31561-7.
Cell.Available online 25 October 2018.
Cell.2018 Sep 27. pii: S0092-8674(18)31183-8.
Cell.2018 Jun 28;174(1):172-186.e21.
Cell.2018 Feb 22;172(5):1007-1021.e17.
Cell.2017 Nov 30;171(6):1284-1300.e21.
Cell.2017 Aug 17. pii: S0092-8674(17)30869-3.
Cell.2017 Jul 13;170(2):312-323
Nat Med.2018 Jan 29.
Nat Med.2017 Nov;23(11):1342-1351.
Cell.2017 Apr 6;169(2):286-300.
Cell.2015 Aug 27;162(5):987-1002.
Cell.2015 Feb 12;160(4):729-44.
Nature Medicine.2017 Apr;23(4):493-500.
Cancer Cell.2018 May 14;33(5):905-921.e5.
Cancer Cell.2018 Apr 9;33(4):752-769.e8.
Cancer Cell.2018 Mar 12;33(3):401-416.e8.
Cancer Cell.2017 Aug 14;32(2):253-267.e5.
Nat Methods.2018 Jul;15(7):523-526.
Cell Stem Cell.2018 May 3;22(5):769-778.e4.
Cell Stem Cell.2017 Nov 20. pii: S1934-5909(17)30375-2.Quality Control & MSDS
- View current batch:
- Purity = 99.84%
- COA (Certificate Of Analysis)
- HPLC
- MS (Mass Spectrometry)
- MSDS (Material Safety Data Sheet)
Chemical structure


Insulin (human) recombinant expressed in yeast Dilution Calculator
calculate

Insulin (human) recombinant expressed in yeast Molarity Calculator
calculate
| Cas No. | 11061-68-0 | SDF | N/A |
| Synonyms | N/A | ||
| Chemical Name | N/A | ||
| Canonical SMILES | N/A | ||
| Formula | C257H383N65O77S6 | M.Wt | 5807.57 |
| Solubility | <58.08mg l="" in="" h2o="">58.08mg> | Storage | Store at -20°C |
| Physical Appearance | White solid | Shipping Condition | Evaluation sample solution : ship with blue ice.All other available size:ship with RT , or blue ice upon request |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. | ||
IC50: 5.01 nmol/L for insulin receptor
Insulin is a peptide hormone produced by beta cells in pancreas. Insulin has been found to stimulate glucose uptake into muscle and adipose tissue, which is central to the maintenance of whole body glucose homeostasis. Autoimmune destruction of the β-cells in pancreas leads to a lack of insulin production and the development of type I and II diabetes mellitus.
In vitro: Methotrexate (MTX) was found to be linked to insulin covalently. As effectively as insulin, insulin-MTX complex competed with 125I-insulin for insulin receptor. It was found that IC50 and Ki for insulin-MTX were 93.82 nM and 91.88 nM, respectively, whereas those for insulin were 5.01 nM and 4.85 nM, respectively [1].
In vivo: Previous study showed that insulin-stimulated glucose uptake in extensor muscles from SJL mice was reduced, but the basal uptake rates were not different. In another mouse study, knockdown of TC10α but not TC10β in 3T3-L1 adipocytes resulted in a inhibition of both insulin-stimulated glucose uptake and GLUT4 translocation [2].
Clinical trial: Clinical study shows that when insulin levels fails, diabetes mellitus can happen. Thus, insulin is medically used to treat some forms of diabetes mellitus. Biosynthetic human insulin for clinical use is manufactured by recombinant DNA technology. Insulin is often taken as subcutaneous injections . Morevoer, inhaled insulin is currently also available in U.S. market (https://en.wikipedia.org/wiki/Insulin#Medication_uses).
References:[1] Ou X,Kuang A,Liang Z,Peng X,Zhong Y. The binding characteristics of insulin-MTX to insulin receptor. Hua Xi Yi Ke Da Xue Xue Bao.2001 Dec;32(4):538-40.[2] Leney SE,Tavaré JM. The molecular basis of insulin-stimulated glucose uptake: signalling, trafficking and potential drug targets. J Endocrinol.2009 Oct;203(1):1-18.


